This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

SVP-Rapamycin/Anc80

Selecta Biosciences, Inc.

Drug Names(s): SEL-110/Anc80, SVP-Rapamycin/Anc80 vector, SVP-Rapamycin + Anc80

Description: Selecta is creating an immunotherapy that combines Anc80, a proprietary gene-therapy vector, with SVP-Rapamycin (SEL-110). SVP is the company's Synthetic Vaccine Particle platform that incorporates antigens and immunomodulators into biodegradable particles.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug